■比较孕激素促排卵(PPOS)方案中的地屈孕酮(DYG)和甲羟孕酮(MPA)对卵巢反应不良(POR)患者的临床结果。
■这是一项回顾性队列研究。纳入2020年1月至2021年1月在郑州大学第三附属医院生殖中心接受IVF/ICSI的POR女性。我们研究的主要结果指标是回收的卵母细胞数量。本研究的次要结局指标是2PN的数量,可用胚胎的数量,取卵率,受精率,每个回收的卵母细胞的存活胚胎率,第一个胚胎移植周期的取消率和妊娠结局,包括生化妊娠,临床妊娠和流产率。
■总共,118名女性接受了hMG+DYG协议,692名接受hMG+MPA的女性符合博洛尼亚POR标准.在使用PSM模型平衡基线特征后,118hMG+DYG方案与118hMG+MPA方案相匹配,两组的基线特征具有可比性.检索到的卵母细胞数量,2PN,可用的胚胎和卵母细胞提取率,受精率,hMGDYG和hMGMPA方案的每个卵母细胞的活胚胎率和取消率具有可比性。总之,hMG+DYG组66名妇女和hMG+MPA组87名妇女进行了首次胚胎移植。在hMG+DYG组中,81.8%(54/66)的患者接受了卵裂胚胎移植;同样,hMG+MPA组中79.3%(69/87)的患者有卵裂胚胎移植(P=0.70)。hMG+DYG组生化妊娠率为42.4%,这与hMG+DYG组的比率相当,34.5%(P=0.32)。两组的临床妊娠率相似(36.4%vs.31.0%,P=0.49),两组之间的流产率没有显着差异(12.5%vs.29.6%,P=0.14)。
■对于患有POR的女性,hMG+DYG组的临床结果与hMG+MPA组相似,表明这两种组合都可以是PPOS协议的有用选项。
UNASSIGNED: To compare the clinical outcomes of dydrogesterone (DYG) and
medroxyprogesterone (MPA) in the progestin-primed ovarian stimulation (PPOS) protocol for patients with poor ovarian response (POR).
UNASSIGNED: This was a retrospective cohort study. Women with POR who underwent IVF/ICSI at the Reproductive Center of Third Affiliated Hospital of Zhengzhou University between January 2020 and January 2021 were included. The primary outcome measure of our study was the number of oocytes retrieved. The secondary outcome measures in the present study were the number of 2PN, number of available embryos, oocyte retrieval rate, fertilization rate, viable embryo rate per oocyte retrieved, cancellation rate and pregnancy outcomes of the first embryo transfer cycle, including the biochemical pregnancy, clinical pregnancy and miscarriage rates.
UNASSIGNED: In total, 118 women underwent hMG +DYG protocols, and 692 women who underwent hMG +MPA met the Bologna criteria for POR. After baseline characteristics were balanced using the PSM model, 118 hMG +DYG protocols were matched to 118 hMG +MPA protocols, and the baseline characteristics were comparable between the two groups. The numbers of oocytes retrieved, 2PN, and available embryos and the oocyte retrieval rate, fertilization rate, viable embryo rate per oocyte retrieved and cancellation rate of the hMG+DYG and hMG+MPA protocols were comparable. Altogether, 66 women in the hMG+DYG group and 87 women in the hMG+MPA group underwent first embryo transfers. In the hMG+DYG group, 81.8% (54/66) of the patients underwent cleavage embryo transfers; similarly, 79.3% (69/87) of patients in the hMG+MPA group had cleavage embryo transfers (P=0.70).The biochemical pregnancy rate of the hMG+DYG group was 42.4%, and this was comparable to the rate in the hMG+DYG group, at 34.5% (P=0.32). The clinical pregnancy rates were similar between the two groups (36.4% vs. 31.0%, P=0.49), and there was no significant difference in the rate of miscarriage between the two groups (12.5% vs. 29.6%, P=0.14).
UNASSIGNED: For women with POR, the clinical outcome of the hMG + DYG group was similar to that of the hMG + MPA group, indicating that both combinations can be useful options for PPOS protocols.